However, if it is joined in
the cell by another influenza virus, it retains its harmless nature but starts to reproduce - and at a much faster rate than the new influenza virus.
Not exact matches
«The holy grail is to target a piece of the
virus by antibody or t
cell,» Tom Evans, the CEO of a company called Vaccitech that is working on a universal vaccine they hope can be used to treat all strains of
influenza A, told National Geographic.
However, compared to other avian
influenza viruses, the attachment to epithelial
cells by H7N9 in the bronchioles and alveoli of the lung was more abundant and the
viruses attached to a broader range of
cell types.
By developing a new technique for labeling the gene segments of
influenza viruses, researchers now know more about how
influenza viruses enter the
cell and establish
cell co-infections — a major contributing factor to potential pandemic development.
The specificity of the approach enabled the researchers to visualize the delivery of the eight
influenza genome segments to the
cell nucleus where the
virus replicates, and to analyze co-infections
by two
influenza viruses that differed
by single mutations.
A study published March 7th
by Cell Press in the journal
Cell reveals that a compound derived from fats found in fish oils prevents death in
influenza -
virus - infected mice, even at advanced stages of disease.
At Emory, the pause has halted not only the CEIRS project with the lab - attenuated PR8 strain, but also a research grant project headed
by Anice Lowen that is looking at how the
cell types targeted
by two different
influenza viruses affect their propensity to exchange genes.
MxA is thought to target
influenza A
by binding to the nucleoprotein that encapsulates the
virus» genome, and mutations in this nucleoprotein have been linked to the
virus» ability to infect human
cells.
The study relates to a particular type of vaccine (killed) against a particular
virus,
influenza, though the findings might hold true for other killed vaccines and for those vaccines consisting only of proteins produced
by GM in bacteria, yeast or insect
cells, against diseases such as hepatitis B (HBV) and human papilloma
virus (HPV, the causative agent of cervical cancer).
A recent study led
by BSI member Professor Andrew Sewell from Cardiff University and published in the Journal of Clinical Investigation showed that a synthetic «mirror image» version of a protein belonging to the
influenza A
virus generated strong immune responses in human
cells and mice, with the mice also being protected when exposed to a strain of
influenza A.
The researchers were able to visualize the delivery of the eight
influenza genome segments to the
cell nucleus where the
virus replicates, and to analyze co-infections
by two
influenza viruses that differed
by single mutations.
Long - lived intermediate states formed
by glycoprotein catalysts are an essential part of the process used
by influenza virus particles to infect
cells.
The
influenza virus invades
cells by puncturing the
cell wall with the tiny spikes of hemaGglutinin that cover its surface.